Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2

Neuro Oncol. 2013 Aug;15(8):972-8. doi: 10.1093/neuonc/not088. Epub 2013 Jul 14.

Abstract

The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate endpoints. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology.

Keywords: Bayesian; adaptive; biomarker; clinical trials; glioblastoma.

Publication types

  • Review

MeSH terms

  • Biomarkers / analysis*
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / therapy*
  • Clinical Trials as Topic*
  • Diagnostic Imaging*
  • Glioblastoma / diagnosis
  • Glioblastoma / therapy*
  • Humans
  • Research Design*

Substances

  • Biomarkers